When to Increase Your Vyvanse Dosage

A Vyvanse dose increase is worth discussing with your prescriber when your core symptoms of inattention, impulsivity, or binge eating remain inadequately controlled after you’ve been on a stable dose long enough for it to reach full effect, and when the side effects you’re experiencing are tolerable. That “long enough” window is usually at least one to two weeks at each dose level, because the medication needs consistent daily exposure to show its real impact on your functioning. The decision is never just about whether the drug “feels like it’s working” on a given afternoon; it hinges on a pattern of symptom control, side-effect burden, and sometimes factors you might not have considered, like your menstrual cycle or a coexisting anxiety disorder.

How Vyvanse Releases Its Active Ingredient

Vyvanse (lisdexamfetamine) is a prodrug, meaning it’s pharmacologically inactive until your body converts it. After you swallow a capsule, the molecule is absorbed from the small intestine through an active carrier transport system. The actual conversion to d-amphetamine, the part that helps your symptoms, happens inside your red blood cells. An enzyme in the cytosol of those cells clips the lysine amino acid off the lisdexamfetamine molecule, freeing d-amphetamine gradually into your bloodstream.¹ This enzymatic step is what gives Vyvanse its relatively smooth onset and long duration compared to immediate-release stimulants. It also means you can’t speed up the conversion by crushing or snorting the capsule contents, which was part of the drug’s design.

Understanding this mechanism matters for dosing because the conversion is rate-limited. In a pharmacokinetic study of children with ADHD receiving single doses of 30, 50, or 70 mg, peak blood levels of d-amphetamine arrived at roughly 3.5 hours after each dose, and the overall exposure scaled proportionally with the dose.² That dose-proportional relationship is reassuring: if 30 mg gives you a certain blood level, 50 mg will give you proportionally more, not a wildly unpredictable jump. It makes titration more predictable than with some other medications.

The Standard Titration Approach

For ADHD, most prescribers start at 30 mg once daily in the morning and increase by 10 or 20 mg at weekly intervals, depending on symptom response and tolerability. The approved dose range for ADHD is 30 to 70 mg per day, and 70 mg is the maximum studied in clinical trials.³ Going above 70 mg is off-label and not supported by controlled trial data.

The goal of titration isn’t to find the highest dose you can tolerate. It’s to find the lowest dose that provides adequate symptom control with acceptable side effects. In a large adult ADHD trial, nearly 95% of participants successfully reached their randomly assigned dose, but fewer people assigned to the higher doses actually attained them, often because side effects became a limiting factor. Importantly, higher baseline symptom severity predicted a stronger response to higher doses, particularly for hyperactive-impulsive symptoms.³ In practical terms, someone with very pronounced symptoms may genuinely need 70 mg, while someone with milder inattention might do perfectly well at 30 or 40 mg.

Signs Your Dose May Be Too Low

The clearest signal is that your target symptoms haven’t improved enough despite taking the medication consistently for at least a week or two. For ADHD, that means you’re still struggling to sustain attention during tasks, losing track of conversations, missing deadlines, or finding it hard to sit through a meeting despite the medication being active in your system. The key phrase is “during the medication’s active window.” Vyvanse typically provides coverage for about 10 to 14 hours. If your symptoms are well-controlled for the first six hours but fall apart by evening, the issue might be duration rather than dose, and that’s a different conversation with your prescriber.

Other signs worth noting for your prescriber include:

Inconsistent benefit: The medication helps on some days but not others, even though nothing else has changed in your routine, sleep, or diet.
Partial response: You notice improvement in one domain (say, focus at work) but not another (emotional regulation or impulsivity) that also bothered you before starting the medication.
Wearing off early: Symptom relief fades well before 10 hours, suggesting the effective blood level isn’t high enough to sustain coverage through the drug’s expected window.

None of these are reasons to increase the dose on your own. They’re data points to bring to your prescriber so the two of you can decide together whether a dose adjustment, a timing change, or even a switch to a different medication makes more sense.

Tolerance Versus Incomplete Titration

One of the most common reasons people think they need a dose increase is that the medication “stopped working.” This is where the distinction between pharmacological tolerance and the natural fading of early side effects becomes important. When you first start a stimulant, you often notice a burst of energy, heightened mood, or a sense of euphoria. Those are side effects of the initial dopamine surge, not the therapeutic effect on attention. Over the first few weeks, those feelings usually diminish. The Canadian ADHD treatment guidelines specifically address this, noting that patients sometimes confuse the energetic or mood-related side effects with the clinical effect on attention and behavior. Even after that initial buzz fades, the improvement in sustained attention typically remains.⁴

True pharmacological tolerance, where the same dose of medication actually becomes less effective at controlling your core symptoms over time, is less common than many people assume. If you find yourself thinking “this isn’t working anymore” after a few weeks on a new dose, it’s worth asking yourself a pointed question: is your ability to focus on boring tasks actually worse than it was at the start, or do you just not feel the drug kicking in the way you did initially? If your work output, task completion, and ability to follow through on plans are still better than they were before medication, the dose may be just fine. If those functional measures truly are slipping despite consistent medication use, good sleep, and no new stressors, then genuine tolerance or under-dosing is a possibility worth raising.

Side Effects That Signal You Shouldn’t Go Higher

Every dose increase is a tradeoff. A long-term safety study of children and adolescents on Vyvanse found that about three-quarters of participants experienced at least one side effect that the investigators attributed to the medication. The most common were decreased appetite (affecting about half the group), weight loss (roughly one in five), and insomnia (about one in eight).⁵ These same side effects occur in adults, though the rates differ somewhat.

If you’re already dealing with significant appetite suppression, difficulty falling asleep, elevated heart rate or blood pressure, jaw clenching, or anxiety at your current dose, pushing the dose higher will usually make those problems worse. In that situation, the conversation with your prescriber shifts from “should we go up?” to “is there a way to manage these side effects at the current dose, or should we try a different approach entirely?” Sometimes the answer is adjusting timing, adding a behavioral strategy for sleep, or switching to a non-stimulant medication. A dose increase shouldn’t happen in a vacuum where only symptom control is considered and side-effect burden is ignored.

When Anxiety Complicates the Picture

Anxiety disorders are extremely common alongside ADHD. Estimates suggest that somewhere between 65% and 90% of adults with ADHD have at least one additional condition, and generalized anxiety disorder is one of the most frequent.⁶ This creates a genuine dilemma during dose titration, because stimulants can worsen anxiety as a side effect. If you raise your Vyvanse dose and your focus improves but you start having panic attacks, that’s not a win.

The nuance, though, is that some anxiety in people with ADHD is actually caused by the ADHD itself. Chronic disorganization, missed deadlines, and the constant feeling of being behind can generate enormous anxiety. In those cases, adequately treating the ADHD with stimulants can actually reduce anxiety rather than increase it.⁶ Teasing apart “anxiety worsened by the stimulant” from “anxiety that would improve if the stimulant dose were optimized” is one of the trickier clinical judgments your prescriber has to make. If you notice your anxiety spiking after a dose increase, document when it happens relative to taking the medication, what triggers it, and whether it feels different from your usual anxiety patterns. That information helps your prescriber figure out which type you’re dealing with.

Dosing for Binge Eating Disorder

Vyvanse is also approved for moderate-to-severe binge eating disorder in adults, and the dosing considerations are different from ADHD. In clinical trials for BED, the 30 mg dose was essentially no better than placebo at reducing binge eating days per week. The meaningful effects showed up at 50 and 70 mg, with large effect sizes at both doses.⁷ This means that if you’re on Vyvanse for BED and you’re still at 30 mg, a dose increase isn’t just reasonable; the evidence suggests the lower dose isn’t likely to help much.

The BED trials typically used a dose-optimization period where patients were titrated to either 50 or 70 mg over the first four weeks, then maintained at that dose. Longer-term data, including a 26-week randomized withdrawal study, showed that continuing lisdexamfetamine at 50 to 70 mg markedly reduced the risk of relapse compared to switching to placebo.⁸ If your prescriber started you low and you haven’t seen benefit, reaching the therapeutic range of 50 to 70 mg is where the evidence says the drug actually works for this condition.⁹

Tracking Your Response Before and After a Change

One of the biggest obstacles to good dose optimization is that people rely on gut feeling rather than structured tracking. Clinicians use standardized scales to assess ADHD symptoms and treatment response, including clinician-rated scales and patient self-report checklists that capture each of the core symptom domains.¹⁰ You don’t need the formal tools your psychiatrist uses, but having some system of your own helps enormously.

Before a dose change, spend a week logging a few things daily: how many hours of productive focus you managed, how many times you caught yourself losing track of a task, whether you had trouble sleeping, and whether you ate adequate meals. After the dose change, continue the same log. This gives you and your prescriber concrete data instead of “I think it’s maybe a little better?” It also helps catch side effects early. If your sleep log shows you’re falling asleep 90 minutes later than before the dose increase, that’s actionable information. If your productivity log shows you gained an extra two hours of usable focus per day, that’s evidence the increase was worth it.

Hormonal Fluctuations and Dosing in Women

This is an area of prescribing that gets far less attention than it deserves. Research into sex-specific pharmacotherapy for ADHD has highlighted that estrogen levels influence dopamine neurotransmission. During the luteal phase of the menstrual cycle, as estrogen drops, dopamine signaling can become further impaired in women with ADHD, worsening both mood and ADHD symptoms. This may explain why a Vyvanse dose that works well for two or three weeks of the month suddenly feels inadequate in the days leading up to a period.¹¹

The hypothesis that has emerged from this research is that a premenstrual increase in psychostimulant dosage could help compensate for the cyclical hormonal dip. This isn’t yet a widespread guideline, but it’s a legitimate and growing area of clinical interest. If you notice a clear pattern where your medication feels less effective during the week before your period, it’s worth bringing this up with your prescriber. Rather than raising your baseline dose permanently (which might be too much during the rest of the month), a targeted adjustment during the luteal phase could be a more precise solution. Tracking your symptoms across your cycle for two to three months before requesting a change gives your prescriber the evidence they need to act on this.

Brand-Name Versus Generic Formulations

Vyvanse lost patent exclusivity relatively recently, and generic lisdexamfetamine is now available. A natural question is whether switching between brand and generic, or between different generic manufacturers, could affect how well the drug works at a given dose. Bioequivalence studies have compared generic capsule formulations against the brand-name product and found that the rate and extent of drug absorption fall within the standard regulatory window, meaning the generic delivers a very similar amount of active drug into your bloodstream.¹²

That said, “bioequivalent” doesn’t mean “identical.” Regulatory agencies allow a range of variation between brand and generic formulations, typically plus or minus 20% for peak concentration and total exposure. In one study, the generic formulation’s peak blood levels ran about 6% higher than the brand, well within the acceptable range. For most people, this difference is imperceptible. But if you’re someone who is finely tuned to your current dose, a switch between manufacturers could theoretically nudge your effective exposure slightly up or down. If you notice a change in symptom control or side effects shortly after switching manufacturers and nothing else in your life has changed, it’s reasonable to mention it to your prescriber. This isn’t a reason to demand a dose increase; it’s a reason to investigate whether the formulation switch itself is the variable.

When a Dose Increase Isn’t the Right Move

Sometimes the right answer is not a higher dose but better conditions for the dose you’re already on. Sleep deprivation substantially blunts stimulant effectiveness. If you’re getting five or six hours of sleep regularly, no dose of Vyvanse is going to work the way it should. Similarly, skipping meals because the medication suppresses your appetite creates a blood-sugar crash later in the day that can mimic medication wearing off. Dehydration, high stress, and concurrent illness can all reduce the apparent effectiveness of your current dose without the dose itself being the problem.

There’s also the question of unrealistic expectations. Vyvanse at the right dose should make it meaningfully easier to initiate and sustain focus, reduce impulsive decisions, and help with emotional regulation. It won’t eliminate all distractibility, make boring tasks interesting, or give you eight hours of laser focus without breaks. If you’ve gone from being unable to start a work project to completing tasks with moderate effort, that might be a good therapeutic response even if it doesn’t feel like the dramatic transformation you expected. The goal is functional improvement, not a neurotypical simulation.

Finally, if you’ve titrated all the way to 70 mg and you’re still not getting adequate relief, the answer isn’t to push beyond the approved maximum. It may mean that lisdexamfetamine isn’t the right medication for you, that a different stimulant formulation would suit your metabolism better, or that a non-stimulant approach should be tried. Some people metabolize the drug differently, and others have comorbidities that require separate treatment before the stimulant can do its job. A ceiling dose that doesn’t produce sufficient benefit is clinical information, not a failure that more milligrams can fix.